NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $133.4 million in its fourth quarter.
On a per-share basis, the Novato, California-based company said it had a loss of $1.39.
The results did not meet Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.24 per share.
The biotechnology company posted revenue of $164.9 million in the period, which topped Street forecasts. Five analysts surveyed by Zacks expected $163.2 million.
For the year, the company reported a loss of $569.2 million, or $6.29 per share. Revenue was reported as $560.2 million.
Ultragenyx expects full-year revenue in the range of $640 million to $670 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE
Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
